Reduced-dose EPOCH-R chemotherapy for elderly patients with advanced stage diffuse large B cell lymphoma

Annals of Hematology
Wen-Hao ZhangRong Tao

Abstract

The standard treatment in elderly patients with diffuse large B cell lymphoma (DLBCL) has not yet been finely established. We investigated the efficacy and safety of rituximab with a reduced-dose of EPOCH chemotherapy in elderly patients who had advanced DLBCL with high IPI scores. The dose of 70% EPOCH was given to patients aged 75 to 79 years, and dose of 50% to patients aged over 80 years. Thirty-one patients with a median age of 79 years (range 75-86 years) were enrolled. Patients received a median of 6 cycle's chemotherapy. The complete response rate was 71.0%. The 3-year overall survival (OS) and progression-free survival rates were 62.8 and 60.3%, respectively. The most frequent grade 3/4 adverse effects were neutropenia (3 patients, 7 events), febrile neutropenia (3 patients, 5 events), and pulmonary infection (3 patients, 3 events). Our study showed that ECOG score 3-4, bulky disease, β2-MG > 5.0 mg/L, and loss of any IADL are prognostic factors for OS in univariate analysis. In summary, reduced-dose EPOCH-R chemotherapy for very elderly patients is very effective with acceptable toxicities. Our preliminary study may provide an alternative approach to manage very elderly fit patients with advanced and poor risk DLBCL b...Continue Reading

References

Aug 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W H WilsonB D Cheson
Oct 31, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M GutierrezW H Wilson
May 4, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P FeugierB Coiffier
Sep 10, 2005·Blood·Lindsay M MortonMartha S Linet
Oct 6, 2005·Cancer·Arti HurriaAlice B Kornblith
Jul 4, 2006·International Journal of Radiation Oncology, Biology, Physics·Naoto ShikamaUNKNOWN Japan Radiation Oncology Group (JAROG)
Jan 9, 2007·Critical Reviews in Oncology/hematology·Ulrich WeddingKlaus Höffken
Mar 28, 2008·Cancer Causes & Control : CCC·Xuesong HanYawei Zhang
Apr 2, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wyndham H WilsonJohn E Janik
Jul 6, 2010·Journal of Cancer Research and Clinical Oncology·Nils WinkelmannUlrich Wedding
Apr 13, 2011·The Lancet Oncology·Frédéric PeyradeUNKNOWN Groupe d'Etude des Lymphomes de l'Adulte (GELA) investigators
Nov 22, 2011·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Ruth PettengellUlrich Jaeger
Nov 15, 2013·The New England Journal of Medicine·Kieron DunleavyWyndham H Wilson
Aug 13, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonT Andrew Lister
Oct 16, 2014·Journal of Chemotherapy·Misato KikuchiYoshinobu Kanda

❮ Previous
Next ❯

Citations

Aug 23, 2020·Current Oncology Reports·Pamela Allen
Mar 7, 2021·Critical Reviews in Oncology/hematology·Alda Tavares, Ilídia Moreira

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.